Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jun;61(6):796-800.
doi: 10.1002/mus.26852. Epub 2020 Mar 20.

Cold aggravates abnormal excitability of motor axons in oxaliplatin-treated patients

Kristine Bennedsgaard  1 , Lise Ventzel  1 , Peter Grafe  2 , Jenny Tigerholm  3 , Andreas C Themistocleous  4 , David L Bennett  4 , Hatice Tankisi  5 , Nanna B Finnerup  1
Affiliations
Clinical Trial

Cold aggravates abnormal excitability of motor axons in oxaliplatin-treated patients

Kristine Bennedsgaard et al. Muscle Nerve. 2020 Jun.

Abstract

Introduction: Cold allodynia is often seen in the acute phase of oxaliplatin treatment, but the underlying pathophysiology remains unclear.

Methods: Patients scheduled for adjuvant oxaliplatin for colorectal cancer were examined with quantitative sensory testing and nerve excitability tests at baseline and after the second or third oxaliplatin cycle at different skin temperatures.

Results: Seven patients were eligible for examination. All patients felt evoked pain and tingling when touching something cold after oxaliplatin infusion. Oxaliplatin decreased motor nerve superexcitability (P < .001), increased relative refractory period (P = .011), and caused neuromyotonia-like after-activity. Cooling exacerbated these changes and prolonged the accommodation half-time.

Discussion: The findings suggest that a combined effect of oxaliplatin and cooling facilitates nerve excitability changes and neuromyotonia-like after-activity in peripheral nerve axons. A possible mechanism is the slowing in gating of voltage-dependent fast sodium and slow potassium channels, which results in symptoms of cold allodynia.

Keywords: allodynia; nerve excitability testing; neuropathy; oxaliplatin toxicity; potassium channel dysfunction; sodium channel dysfunction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
Nerve excitability testing for the motor nerve. A) Strength‐duration time constant, B) threshold electrotonus, and C) recovery cycle. Dark line: baseline; gray line: follow‐up without cooling; blue (triangle) line: follow‐up with cooling. Filled lines: means; dashed lines: standard errors [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
Afterpotentials after maximum CMAP at baseline, follow‐up, and follow‐up with cooling. The number of afterpotentials increased with cooling. Only six of the seven patients are shown due to excess voluntary activity in one patient. CMAP, compound muscle action potential; OXP, oxaliplatin
See this image and copyright information in PMC

References

    1. Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin‐induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33:3416‐3422. - PMC - PubMed
    1. Grothey A. Oxaliplatin‐safety profile: neurotoxicity. Semin Oncol. 2003;30:5‐13. - PubMed
    1. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144:245‐252. - PubMed
    1. Cersosimo RJ. Oxaliplatin‐associated neuropathy: a review. Ann Pharmacother. 2005;39:128‐135. - PubMed
    1. Heide R, Bostock H, Ventzel L, et al. Axonal excitability changes and acute symptoms of oxaliplatin treatment: in vivo evidence for slowed sodium channel inactivation. Clin Neurophysiol. 2018;129:694‐706. - PubMed

Publication types